QL
CBIO

Quarry LP’s Crescent Biopharma CBIO Stock Holding History

Quarry LP’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$522 Buy
+29
New +$566 ﹤0.01% 2154

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Quarry LP's CBIO Position: Q2 2026 in Review

Quarry LP opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 29 shares worth $522. The stake represents ﹤0.01% of the portfolio and ranks #2154 among its holdings.

82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Quarry LP held 29 shares of Crescent Biopharma worth $522 as of Q2 2026.
  • Crescent Biopharma was a new Quarry LP position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of Quarry LP's portfolio in Q2 2026, its #2154 holding.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.